CL2011002260A1 - Metodo o sistema para el seguimiento del tratamiento de un individuo que comprende determinar si una muestra de dicho individuo comprende un biomarcador. - Google Patents

Metodo o sistema para el seguimiento del tratamiento de un individuo que comprende determinar si una muestra de dicho individuo comprende un biomarcador.

Info

Publication number
CL2011002260A1
CL2011002260A1 CL2011002260A CL2011002260A CL2011002260A1 CL 2011002260 A1 CL2011002260 A1 CL 2011002260A1 CL 2011002260 A CL2011002260 A CL 2011002260A CL 2011002260 A CL2011002260 A CL 2011002260A CL 2011002260 A1 CL2011002260 A1 CL 2011002260A1
Authority
CL
Chile
Prior art keywords
individual
biomarker
monitoring
sample
treatment
Prior art date
Application number
CL2011002260A
Other languages
English (en)
Spanish (es)
Inventor
Tokuzo Kudo Kanae Nakagawa Kasihiko Nishio Kasuto Arao
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002260(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2011002260A1 publication Critical patent/CL2011002260A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2011002260A 2009-03-12 2011-09-12 Metodo o sistema para el seguimiento del tratamiento de un individuo que comprende determinar si una muestra de dicho individuo comprende un biomarcador. CL2011002260A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09154964 2009-03-12

Publications (1)

Publication Number Publication Date
CL2011002260A1 true CL2011002260A1 (es) 2012-03-23

Family

ID=42129920

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002260A CL2011002260A1 (es) 2009-03-12 2011-09-12 Metodo o sistema para el seguimiento del tratamiento de un individuo que comprende determinar si una muestra de dicho individuo comprende un biomarcador.

Country Status (24)

Country Link
US (1) US8802384B2 (enExample)
EP (1) EP2406628A1 (enExample)
JP (1) JP5667581B2 (enExample)
KR (1) KR20110137307A (enExample)
CN (1) CN102334030A (enExample)
AR (1) AR076113A1 (enExample)
AU (1) AU2010223256B2 (enExample)
BR (1) BRPI1011688A2 (enExample)
CA (1) CA2755055A1 (enExample)
CL (1) CL2011002260A1 (enExample)
CO (1) CO6430497A2 (enExample)
EA (1) EA201101300A1 (enExample)
EC (1) ECSP11011323A (enExample)
IL (1) IL214747A0 (enExample)
MA (1) MA33120B1 (enExample)
MX (1) MX2011009482A (enExample)
NZ (1) NZ594843A (enExample)
PE (1) PE20120592A1 (enExample)
SG (1) SG174324A1 (enExample)
TN (1) TN2011000457A1 (enExample)
TW (1) TW201100802A (enExample)
UA (1) UA107789C2 (enExample)
UY (1) UY32482A (enExample)
WO (1) WO2010103058A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
NO2299987T3 (enExample) * 2008-06-06 2018-07-21
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2018081236A1 (en) * 2016-10-28 2018-05-03 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1571225A1 (en) 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2008103B1 (en) 2006-04-18 2010-07-28 Wellstat Biologics Corporation Detection of circulating endothelial cells
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
CN101512017A (zh) * 2006-09-07 2009-08-19 阿斯利康(瑞典)有限公司 评价用靶向ret受体酪氨酸激酶的药物治疗的患者的方法
EP2527467A3 (en) 2007-04-13 2013-03-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
US20100184049A1 (en) 2007-04-27 2010-07-22 Steve Goodison Glycoprotein Profiling of Bladder Cancer

Also Published As

Publication number Publication date
PE20120592A1 (es) 2012-06-09
AR076113A1 (es) 2011-05-18
JP5667581B2 (ja) 2015-02-12
NZ594843A (en) 2014-03-28
UY32482A (es) 2010-10-29
EP2406628A1 (en) 2012-01-18
BRPI1011688A2 (pt) 2016-03-22
AU2010223256B2 (en) 2014-08-21
JP2012520446A (ja) 2012-09-06
ECSP11011323A (es) 2011-10-31
MA33120B1 (fr) 2012-03-01
WO2010103058A1 (en) 2010-09-16
CO6430497A2 (es) 2012-04-30
IL214747A0 (en) 2011-11-30
TN2011000457A1 (en) 2013-03-27
MX2011009482A (es) 2011-09-27
SG174324A1 (en) 2011-10-28
AU2010223256A1 (en) 2011-09-15
TW201100802A (en) 2011-01-01
CN102334030A (zh) 2012-01-25
US8802384B2 (en) 2014-08-12
US20100233705A1 (en) 2010-09-16
KR20110137307A (ko) 2011-12-22
CA2755055A1 (en) 2010-09-16
EA201101300A1 (ru) 2012-04-30
UA107789C2 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
BRPI0907279A2 (pt) sistema de monitoramento fetal e método para o monitoramento fetal.
BRPI0924643A2 (pt) método para realizar uma ação de resgate de elevador,e, sistema de elevador.
BRPI1012125A2 (pt) sistema, método e aparelho para inserção de sensor.
BRPI1013625A2 (pt) sistema, e método para determinar saúde de equipamento
BRPI0917910A2 (pt) método para detectar amostra de aspereza e aparelho para o método
BRPI0908763A2 (pt) Dispositivo, método para a obtenção de uma referência de freqüência e sistema.
BRPI1015100A2 (pt) sistema, dispositivo e método para tratamento de aneurisma.
BR112012010299A2 (pt) método implementado por computador, e, sistema para a realização de um método de caracterização
BRPI0823030A2 (pt) Sistema de elevador, e, método para fazer um sistema de elevador.
BRPI0921757A2 (pt) indicador de posição de válvula, método para determinar uma posição de uma válvula, e , sistema indicador de posição de válvula.
BRPI1012752A2 (pt) método e aparelho para detectar um fenômeno físico.
BRPI0918434A2 (pt) sistema e método para avaliar o som nascido na estrutura.
BR112013020836A2 (pt) método de cimentação e sistema de monitoramento de cimento.
BRPI1013632A2 (pt) sistema, método e aparelho
BRPI0918357A2 (pt) sistema e método para processamento de amostras
BR112012005449A2 (pt) método implementado por computador, e, sistema de computador
BR112012004383A2 (pt) método, aparelho e sistema para predição de espectro
BRPI1014150A2 (pt) método e sistema de diagnose de aparelho.
BRPI0813569A2 (pt) Método de inspeção.
BRPI1012657A2 (pt) método de processamneto de sondagem de decodificador, decodificador e sistema de monitoramento.
BRPI1008733A2 (pt) elevador com sistema de monitoramento
BRPI1015922A2 (pt) sistemas e métodos para testar analitos
BRPI0911371A2 (pt) método de determinação do prognóstico de funcionamento de um sistema
CL2011002260A1 (es) Metodo o sistema para el seguimiento del tratamiento de un individuo que comprende determinar si una muestra de dicho individuo comprende un biomarcador.
IT1393308B1 (it) Dispositivo e procedimento per localizzare scariche parziali.